FDA expands Eli Lilly’s Jaypirca to first‑line treatment for untreated CLL/SLL without 17p deletion
On 2 Oct 2026 the U.S. Food and Drug Administration approved Eli Lilly’s Jaypirca (pirtobrutinib) for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who lack a 17p deletion. The decision is based on the Phase 3 BRUIN CLL‑313 trial, which showed a hazard ratio of 0.20 for progression‑free survival versus bendamustine‑rituximab. The label adds a first‑line indication to the drug’s existing approvals for relapsed or refractory disease.
Why it matters
The company says the expanded label will increase Jaypirca’s market opportunity in the CLL/SLL space. Analysts note that adding a first‑line indication could boost sales volume and improve Lilly’s oncology pipeline outlook.
Key facts
- 1The FDA approval was announced on 2 Oct 2026. prnewswire.com
- 2Jaypirca is now approved for first‑line treatment of adult CLL/SLL patients without a known 17p deletion. prnewswire.com
- 3In the BRUIN CLL‑313 trial, the primary endpoint of IRC‑assessed progression‑free survival showed a hazard ratio of 0.20 (95 % CI 0.11–0.37; p < 0.0001). prnewswire.com
- 4Median follow‑up in the trial was 28 months. prnewswire.com
- 5The trial enrolled 141 patients in each arm (pirtobrutinib vs. bendamustine + rituximab). prnewswire.com
- 6Overall response rate was 94 % (95 % CI 89–98) for pirtobrutinib and 81 % (95 % CI 73–87) for the comparator. prnewswire.com
Summary written by AlphAI from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.